| Combination chemotherapy in advanced adrenocortical carcinoma M Fassnacht, M Terzolo, B Allolio, E Baudin, H Haak, A Berruti, S Welin, ... New England Journal of Medicine 366 (23), 2189-2197, 2012 | 510 | 2012 |
| Integrated genomic characterization of adrenocortical carcinoma G Assié, E Letouzé, M Fassnacht, A Jouinot, W Luscap, O Barreau, ... Nature genetics 46 (6), 607, 2014 | 348 | 2014 |
| Adrenocortical carcinoma: a clinician's update M Fassnacht, R Libé, M Kroiss, B Allolio Nature Reviews Endocrinology 7 (6), 323, 2011 | 335 | 2011 |
| Update in adrenocortical carcinoma M Fassnacht, M Kroiss, B Allolio The Journal of Clinical Endocrinology & Metabolism 98 (12), 4551-4564, 2013 | 291 | 2013 |
| Comprehensive pan-genomic characterization of adrenocortical carcinoma S Zheng, AD Cherniack, N Dewal, RA Moffitt, L Danilova, BA Murray, ... Cancer cell 29 (5), 723-736, 2016 | 244 | 2016 |
| Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study M Fassnacht, A Berruti, E Baudin, MJ Demeure, J Gilbert, H Haak, ... The lancet oncology 16 (4), 426-435, 2015 | 177 | 2015 |
| Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection F Beuschlein, J Weigel, W Saeger, M Kroiss, V Wild, F Daffara, R Libé, ... The Journal of Clinical Endocrinology & Metabolism 100 (3), 841-849, 2015 | 137 | 2015 |
| Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma S Wortmann, M Quinkler, C Ritter, M Kroiss, S Johanssen, S Hahner, ... European journal of endocrinology 162 (2), 349-356, 2010 | 117 | 2010 |
| Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial M Kroiss, M Quinkler, S Johanssen, NP van Erp, N Lankheet, A Pöllinger, ... The Journal of Clinical Endocrinology & Metabolism 97 (10), 3495-3503, 2012 | 113 | 2012 |
| The role of surgery in the management of recurrent adrenocortical carcinoma I Erdogan, T Deutschbein, C Jurowich, M Kroiss, C Ronchi, M Quinkler, ... The Journal of Clinical Endocrinology & Metabolism 98 (1), 181-191, 2013 | 104 | 2013 |
| Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma M Kroiss, M Quinkler, WK Lutz, B Allolio, M Fassnacht Clinical Endocrinology 75 (5), 585-591, 2011 | 102 | 2011 |
| Mitotane inhibits sterol-O-acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells S Sbiera, E Leich, G Liebisch, I Sbiera, A Schirbel, L Wiemer, S Matysik, ... Endocrinology 156 (11), 3895-3908, 2015 | 95 | 2015 |
| Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection M Terzolo, AE Baudin, A Ardito, M Kroiss, S Leboulleux, F Daffara, ... European journal of endocrinology 169 (3), 263-270, 2013 | 89 | 2013 |
| Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study R Libe, I Borget, CL Ronchi, B Zaggia, M Kroiss, T Kerkhofs, J Bertherat, ... Annals of Oncology 26 (10), 2119-2125, 2015 | 86 | 2015 |
| Evolution of an RNP assembly system: a minimal SMN complex facilitates formation of UsnRNPs in Drosophila melanogaster M Kroiss, J Schultz, J Wiesner, A Chari, A Sickmann, U Fischer Proceedings of the National Academy of Sciences 105 (29), 10045-10050, 2008 | 78 | 2008 |
| Tdrd3 is a novel stress granule-associated protein interacting with the Fragile-X syndrome protein FMRP B Linder, O Plöttner, M Kroiss, E Hartmann, B Laggerbauer, G Meister, ... Human molecular genetics 17 (20), 3236-3246, 2008 | 77 | 2008 |
| Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer A Berruti, M Fassnacht, H Haak, T Else, E Baudin, P Sperone, M Kroiss, ... European urology 65 (4), 832-838, 2014 | 67 | 2014 |
| Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatographytandem mass spectrometry: utility for diagnosis of dopamine … M Peitzsch, A Prejbisz, M Kroiß, F Beuschlein, W Arlt, A Januszewicz, ... Annals of clinical biochemistry 50 (2), 147-155, 2013 | 66 | 2013 |
| Prognostic impact of subclinical thyroid dysfunction in heart failure A Frey, M Kroiss, D Berliner, M Seifert, B Allolio, G Güder, G Ertl, ... International journal of cardiology 168 (1), 300-305, 2013 | 57 | 2013 |
| No endogenous ouabain is detectable in human plasma by ultra-sensitive UPLC-MS/MS S Baecher, M Kroiss, M Fassnacht, M Vogeser Clinica Chimica Acta 431, 87-92, 2014 | 54 | 2014 |
